MStranslate

08/12/2025

The European Committee for Treatment & Research in Multiple Sclerosis have just published the Impact Report from Patient Community Day 2025. This is a great opportunity to explore the key research highlights from the event and get insights from people throughout the MS community.

Since 2022, Patient Community Day (PCD) has grown from a modest beginning into a global legacy initiative uniting thousands of people living with MS, NMOSD, and MOGAD with the scientific community that serves them. What began as an advancement in accessibility and inclusion has become a recognised p...

05/12/2025

Mental health is such an important topic, but one we don't talk about often enough. Join Brett in this live broadcast and let's have an open and honest conversation about it!

04/12/2025

VOTE NOW: Since being diagnosed with multiple sclerosis, I have talked to a psychologist (react with LOVE for YES or WOW for NO)

03/12/2025

Today is International Day of People with Disability - Australia, a moment to recognise the strength, diversity and contributions of people living with disabilities – including those in our MS community. This year’s theme, “Fostering disability-inclusive societies for advancing social progress,” is a reminder that true progress in MS depends on inclusion: in research, in clinical trials, in care and in every conversation that shapes our future. By ensuring people with MS are heard, represented and empowered, we can drive better science, better support, and better outcomes for all. Thank you to everyone who helps make this page such a diverse, inclusive and supportive community.

28/11/2025

As the holidays approach, MS Australia have published their travel tips for people living with multiple sclerosis. What strategies do you use when you travel to make things easier and less stressful?

Travelling with MS can be incredibly rewarding, but it requires thoughtful preparation to ensure comfort, safety, and accessibility. With the right strategies, you can enjoy less stressful adventures and make the most of your journey.

26/11/2025

Researchers are launching a new trial of an mRNA vaccine targeting Epstein–Barr virus (EBV) to see whether it can help treat people with relapsing MS. Unlike traditional therapies that suppress the immune system, this vaccine aims to help the body better control EBV and potentially reduce MS activity.

The pharmaceutical company Moderna is launching a new trial to see if a vaccine against Epstein-Barr virus (EBV) can help treat people with relapsing MS.

25/11/2025

A new Canadian study, led by researchers at Dalhousie University, is exploring how both biological factors and social experiences influence outcomes for people living with MS. The project aims to better understand why some people face greater challenges than others and how care can be made more personalised and equitable. Importantly, it’s designed to include groups who have been under-represented in MS research.

Dalhousie researcher leads a $2M national study to explore how biological and social factors impact health outcomes for Canadians living with multiple sclerosis, aiming for more equitable care.

24/11/2025

BREAKING NEWS: Contineum therapeutics have announced via a press release that PIPE-307, their potential myelin repair agent for multiple sclerosis, has failed in a Phase 2 clinical trial. While this news is obviously disappointing, understanding the reasons this approach didn't work will help guide the development of future remyelination therapies. We will provide further updates on these results once full data is made available.

Press release: https://tinyurl.com/yknphc8v

21/11/2025

We are broadcast live to talk about the latest in remyelination research in multiple sclerosis! Join in the discussion by commenting below.

19/11/2025

On Saturday, we will be discussing the results of the metformin and clemastine remyelination clinical trial. The primary outcome of this trial was a technique called visual evoked potential or VEP. In this short video that we filmed with the Cambridge Clinical Multiple Sclerosis Research Group, they explain what it is and how it can be used to determine the success of a myelin repair therapy.

18/11/2025

New research from the Karolinska Institutet in Sweden is helping us learn more about the role of oligodendrocytes in multiple sclerosis. These cells are particularly important in MS because they produce myelin, so understanding how they behave is essential for advancing remyelination therapies.

A new study from Karolinska Institutet, published in Nature Neuroscience, explores how oligodendrocytes, the cells that produce myelin in the brain and spinal cord, respond during the development of multiple sclerosis. By following these cells in a mouse model, the researchers identified distinct di...

17/11/2025

We are back with a special Facebook Live broadcast to discuss the latest in remyelination research and clinical trial results for people living with multiple sclerosis. Join us this Saturday 22nd November at 9am AEDT to be part of the conversation!